Evidence map›Paper›PMID 39759955›Full record

ReviewExploratory research in clinical and social pharmacy2025

Drug utilisation research and medicine access in Mozambique: An overview.

Roger Wiseman, Ilse Truter

Abstract readReview
In one paragraph

Review in Exploratory research in clinical and social pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Roger WisemanDrug Utilisation Research Unit, Department of Pharmacy, Nelson Mandela University, Gqeberha, South Africa.
Ilse TruterDrug Utilisation Research Unit, Department of Pharmacy, Nelson Mandela University, Gqeberha, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Access to medicine is fundamental to the provision of equitable health systems. However, availability of affordable quality-assured medicines continues to be poor, especially in Low- and Middle-Income Countries (LMICs). Targeted efforts associated with transparency and accountability around medicine utilisation are required in LMICs to address this problem. With the increased global focus on improved access to medicines, there is a heightened imperative to understand the current landscape of medicine prescribing in these territories. In Sub-Saharan Africa, drug utilisation research is generally under-developed due to the lack of access to databases that capture prescribed drug utilisation information. The advent of private health insurance in many African countries, including Mozambique, where the average life expectancy at birth is of the lowest in Sub-Saharan Africa, has created an opportunity to collect comprehensive medicine-related prescription data to facilitate monitoring and evaluation of medicine use thereby assisting in directing medicine-related policy. This overview focuses on Mozambique as one such country where future drug utilisation studies might assist in informing medicine-related health policy and improving medicine access. In addition, it explores drug utilisation as a research methodology and how it might be of assistance in meeting Mozambique's unmet needs.

Indexed as

Drug utilisation researchDrug utilisation reviewMedicine pricingMozambiqueRational drug use

Identifiers

PMID39759955
PMCPMC11699339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.